Seoul revises rule to ease budgetary losses over lawsuits with pharma firms

Lee Hee-jo, Lee Jong-hyuk and Minu Kim 2022. 1. 18. 14:30
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

[Photo by Yonhap]
Korean health authorities will soon apply a new drug reimbursement rule to stop healthcare budget leakage by preventing excessive injunction filings by pharmaceutical companies against the government in administrative lawsuits.

According to the Ministry of Health and Welfare and the National Health Insurance Service (NHIS) on Monday, the revised rule on the criteria for health insurance reimbursement allows pharmaceutical companies to receive compensation from the government for losses from unfavorable administrative measures once they win in a formal court trial.

The revised rule is aimed to save budget losses by preventing the industry from abusing injunction filings before a formal hearing process.

A health ministry official said the revision sends a signal to the court that the government could pay for losses and therefore the court needs to lower its acceptance rate of injunction claims from pharmaceutical companies.

According to data, pharmaceutical plaintiffs filed 44 administrative lawsuits against the government last year. Of these, 17 cases were declared closed where the NHIS won 13 cases. Pharmaceutical companies can leverage an injunction to continue to receive reimbursement benefits until a final court ruling against them is handed down. This time gap cost 408.8 billion won ($343 million) in the healthcare budget over the past five years.

The health ministry had sought a different revision to force pharmaceutical companies to return any gains from accepted injunctions before their defeat in a final ruling, but the revision failed to pass the legislative and judiciary committee of the National Assembly last Monday due to a potential infringement of jurisdiction.

[¨Ï Maeil Business Newspaper &, All rights reserved]

Copyright © 매일경제 & 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?